Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | ANPEP | P15144 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16316628 | 0.80 | USP2 (0.50) | USP2ALDH1A1ANPEPMEN1KMT2A | |
| SCHEMBL19919871 | 0.80 | USP2 (0.50) | USP2ALDH1A1ANPEPMEN1KMT2A | |
| SCHEMBL19258005 | 0.78 | SIGMAR1 (0.46) | USP2ALDH1A1KMT2ALMNACYP2D6 | |
| SCHEMBL19258136 | 0.78 | SIGMAR1 (0.46) | USP2ALDH1A1KMT2ALMNACYP2D6 | |
| SCHEMBL17789411 | 0.77 | USP2 (0.47) | USP2ALDH1A1ANPEPMEN1KMT2A | |
| SCHEMBL6697709 | 0.74 | USP2 (0.48) | USP2ALDH1A1ANPEPMEN1KMT2A | |
| SCHEMBL24153309 | 0.74 | USP2 (0.44) | USP2ALDH1A1ANPEPMEN1KMT2A | |
| SCHEMBL17828102 | 0.73 | USP2 (0.58) | USP2ALDH1A1ANPEPMEN1KMT2A | |
| SCHEMBL200033 | 0.73 | USP2 (0.58) | USP2ALDH1A1ANPEPMEN1KMT2A | |
| SCHEMBL13066093 | 0.73 | USP2 (0.58) | USP2ALDH1A1ANPEPMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040186160-A1 | Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors | SUGEN, INC. | 2004-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186160-A1 | Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors | MAP3K15, MAP3K20, MAP3K19 | USP2 1332/4885ALDH1A1 3282/4885ANPEP 2129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.